<a href="https://laohu8.com/S/SVRA">Savara Inc</a>. posts Q3 net loss of $29.6 million
Savara Inc. reported a net loss of $29.6 million, or $(0.14) per share, for the third quarter of 2025, compared with a net loss of $24.2 million, or $(0.11) per share, for the same period in 2024. Research and development expenses rose by 1.4% to $20.6 million, primarily due to activities related to the MOLBREEVI program. General and administrative expenses increased by 60.1% to $9.6 million, mainly due to higher personnel costs and commercial activities. As of September 30, 2025, Savara had cash, cash equivalents, and short-term investments of approximately $124.4 million and debt of about $29.8 million. The company recently raised about $140 million through an equity financing and announced a $75 million royalty funding agreement. Savara expects to resubmit the Biologics License Application for MOLBREEVI in December 2025 and to submit marketing authorization applications in Europe and the UK in the first quarter of 2026.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Savara Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251112721405) on November 12, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.